Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 14/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.58 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13829026 | 0.90 | PIK3CA (0.66) | MTORPIK3CAPIK3R1PIK3CDMEN1 | |
| SCHEMBL13828596 | 0.88 | MTOR (0.65) | MTORPIK3CAPIK3CG | |
| SCHEMBL13828881 | 0.87 | MTOR (0.55) | MTORPIK3CAPIK3R1PIK3CDMEN1 | |
| SCHEMBL1373862 | 0.86 | GAA (0.63) | PIK3CAMEN1KMT2AALDH1A1GAA | |
| SCHEMBL12463454 | 0.85 | MTOR (0.62) | MTORPIK3CAPIK3R1PIK3CDMEN1 | |
| SCHEMBL2148462 | 0.84 | MTOR (0.70) | MTORPIK3CAPIK3R1PIK3CD | |
| SCHEMBL13828937 | 0.83 | MTOR (0.44) | MTORPIK3CAPIK3R1PIK3CDMEN1 | |
| SCHEMBL13828927 | 0.83 | PIK3CA (0.60) | MTORPIK3CAPIK3R1PIK3CDPIK3CG | |
| SCHEMBL13828614 | 0.82 | MTOR (0.56) | MTORPIK3CAPIK3R1PIK3CDMEN1 | |
| SCHEMBL13828865 | 0.82 | MEN1 (0.61) | MTORMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | disclosed |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-05-19 | — | — | US | disclosed |
| US-9315491-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-04-19 | — | — | US | disclosed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MTOR 1/4885PIK3CA 2/4885PIK3R1 20/4885 |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MTOR 1/4885PIK3CA 2/4885PIK3R1 20/4885 |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MTOR 1/4885PIK3CA 2/4885PIK3R1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.